The diversity of antibody variants in the biotherapeutics pipeline are increasing with a growing interest for molecules like antibody fragments and bispecific antibodies (bsAbs). Cytiva has published an interactive course that gives an overview of monoclonal antibodies (mAbs) and current variants used and developed in academia and industry.
Key learnings are:
- Structure and binding domains for antibody variants
- Advantages and disadvantages of different antibody fragments
- Design strategies for bispecific antibodies (bsAbs)